- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05384119
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal receptor 2-negative (HER2)- palbociclib-resistant breast cancer, and to determine the recommended Phase 2 dose (RP2D) for TTI-101 when added to palbociclib and AI or fulvestrant.
The primary objective of Phase 2 will be to evaluate anti-tumor activity in participants who receive TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Kari Anne Rowland, MS
- Phone Number: Please email
- Email: info@tvardi.com
Study Contact Backup
- Name: Nicole Goodwin
- Phone Number: Please email
- Email: info@tvardi.com
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Holy Cross Health Fort Lauderdale - Holy Cross Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine Siteman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt - Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- Harold C. Simmons Comprehensive Cancer Center
-
Dallas, Texas, United States, 75246
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must meet all the following criteria to be eligible:
- Age ≥18 years at the time of informed consent.
- Metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
For Phase 1b,currently receiving palbociclib and AI or fulvestrant; for Phase 2, currently receiving palbociclib or ribociclib and AI or fulvistrant therapy in the metastatic setting with evidence of progressive disease. In addition:
- Must have remained on palbociclib or ribociclib and AI or fulvestrant therapy for ≥6 months for advanced breast cancer or metastatic disease prior to evidence of progression that in the opinion of the treating physician warrants continued therapy with palbociclib or ribociclib and AI or fulvestrant.
- Dosage of palbociclib, ribociclib, AI and fulvestrant must remain unchanged from regimen prior to study enrollment specifically palbociclib at a dose of 125, 100, or 75 mg administered orally for 21 days every 28-day cycle or ribociclib at a dose of 200, 400, or 600 mg administered orally for 21 days every 28-day cycle.
- All men and premenopausal women must be on medical gonadal suppression therapy with a gonadotropin analog (e.g, goserelin or leuprolide) and have estrogen levels in the postmenopausal range by institutional criteria at baseline.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has documented confirmation of histological or cytological HR-positive, HER2-negative breast cancer per local laboratory testing.
- Up to 2 prior lines of systemic treatment (most recent line of therapy must be palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2) in the locally advanced or metastatic setting is allowed; the participant must have shown evidence of progressive disease on palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2 in the locally advanced or metastatic setting prior to enrollment.
Willing to provide a representative fresh tumor tissue specimen prior to enrollment. The fresh tumor specimen must be obtained after evidence of progression on palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2.
• Participants with bone only disease WITHOUT a soft tissue component, may opt out of the tumor biopsy.
- The presence of measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 is preferred but not required. Lesions in a previously irradiated area that have not progressed are not considered measurable.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible:
- Has received more than 2 lines of prior systemic therapy for locally advanced/metastatic breast cancer.
- Had prior exposure to any signal transducer and activator of transcription 3 (STAT3) inhibitor.
- Had radiotherapy within 3 weeks prior to Cycle 1 Day 1 (cycle is 28 days). Participants must have recovered from radiotherapy toxicities prior to starting study treatment and recovered to Grade 1 or better from related side effects of such therapy (with the exception of alopecia).
- Has HER2 overexpression by local laboratory testing (immunohistochemical [IHC] 3+ or in situ hybridization positive).
- Has known loss of retinoblastoma tumor suppressor gene (Rb) (testing not mandatory).
- Has had disease progression on more than two cyclin-dependent kinase (CDK)4/6 inhibitors. Adjuvant abemaciclib is allowed but must have progressed on palbociclib or ribociclib.
- Concurrently using other anticancer therapy. Participants must continue palbociclib and AI or fulvestrant for Phase 1b and palbociclib or ribociclib and AI or fulvestrant for Phase 2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b: Dose Escalation
Participants will receive up to 3 dose levels of TTI-101 added to palbociclib and AI or fulvestrant to determine the RP2D.
|
Oral tablet
Oral capsule
Other Names:
Oral tablet
Oral tablet
|
Experimental: Phase 2: Dose Expansion
Enrollment in Phase 2 may commence with approval from the safety review committee.
Participants will be enrolled and treated at the RP2D of TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
|
Oral tablet
Oral capsule
Other Names:
Oral tablet
Oral tablet
Oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Time Frame: Day 1 to Day 28
|
Day 1 to Day 28
|
|
Phase 1b: Number of Participants Who Experience an Adverse Event (AE)
Time Frame: Up to approximately 18 months
|
An AE is any untoward medical occurrence in a participant or clinical study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Any clinically significant changes between baseline and postbaseline laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations will be recorded as AEs.
|
Up to approximately 18 months
|
Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE)
Time Frame: Up to approximately 18 months
|
Up to approximately 18 months
|
|
Phase 2: Landmark Progression Free Sulrvival at 6 Months (PFS6)
Time Frame: Day 1 pre-dose and 6 months post-dose
|
Day 1 pre-dose and 6 months post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b and Phase 2: Overall Response Rate (ORR)
Time Frame: Up to approximately 18 months
|
Defined as complete response (CR) + partial response (PR) measured in all participants using RECIST Version 1.1.
|
Up to approximately 18 months
|
Phase 1b and Phase 2: Overall Response Rate (ORR)
Time Frame: Up to approximately 18 months
|
Defined as complete response (CR) + partial response (PR) measured using RECIST Version 1.1 in participants who have a follow-up on-study tumor assessment at least 42 days following Cycle 1 Day 1 (cycle is 28 days) and who receive at least 80% of scheduled dosing with TTI-101.
|
Up to approximately 18 months
|
Phase 1b and Phase 2: Duration of Response (DoR) to Treatment
Time Frame: Up to approximately 18 months
|
Up to approximately 18 months
|
|
Phase 1b and Phase 2: Time to Tumor Progression (TTP)
Time Frame: Up to approximately 18 months
|
Up to approximately 18 months
|
|
Phase 1b and Phase 2: Best Overall Response (BOR)
Time Frame: Up to approximately 18 months
|
Up to approximately 18 months
|
|
Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of TTI-101
Time Frame: Cycle 2 Day 1 (cycle is 28 days)
|
Cycle 2 Day 1 (cycle is 28 days)
|
|
Phase 1b and Phase 2: Time of Maximum Observed Plasma Concentration (Tmax) of TTI-101
Time Frame: Cycle 2 Day 1 (cycle is 28 days)
|
Cycle 2 Day 1 (cycle is 28 days)
|
|
Phase 1b and Phase 2: Area Under the Plasma Concentration-time Curve from Time 0 to Time t (AUC[0-t]) of TTI-101
Time Frame: Cycle 2 Day 1 (cycle is 28 days)
|
Cycle 2 Day 1 (cycle is 28 days)
|
|
Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 1 (pY-STAT1) Positive Cells in Tumor Biopsy Samples
Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
|
Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 3 (pY-STAT3) Positive Cells in Tumor Biopsy Samples
Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
|
Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples
Time Frame: Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
Baseline to Cycle 3 Day 1 (cycle is 28 days)
|
|
Phase 1b: PFS6
Time Frame: Day 1 pre-dose and 6 months post-dose
|
Day 1 pre-dose and 6 months post-dose
|
|
Phase 1b and Phase 2: Clinical Benefit Rate (CBR)
Time Frame: Up to approximately 18 months
|
Defined as complete response (CR) + partial response (PR) + stable disease (SD) for at least 6 months.
|
Up to approximately 18 months
|
Phase 2: Progression-free Survival (PFS)
Time Frame: Up to approximately 18 months
|
Up to approximately 18 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Palbociclib
- Aromatase Inhibitors
Other Study ID Numbers
- TVD-101-002B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on TTI-101
-
University of Colorado, DenverTvardi Therapeutics, IncorporatedRecruitingPancreatic CancerUnited States
-
Tvardi Therapeutics, IncorporatedM.D. Anderson Cancer CenterActive, not recruitingMelanoma | Breast Cancer | Colorectal Cancer | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Hepatocellular CancerUnited States
-
Tvardi Therapeutics, IncorporatedRecruitingIdiopathic Pulmonary FibrosisUnited States
-
M.D. Anderson Cancer CenterNational Institutes of Health (NIH); Tvardi Therapeutics, IncNot yet recruitingSquamous Cell Carcinoma of Head and NeckUnited States
-
Trillium Therapeutics Inc.CompletedInterstitial CystitisCanada
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
M.D. Anderson Cancer CenterTvardi Therapeutics, IncNot yet recruiting
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
PfizerTerminatedSolid Tumor | Hematologic MalignanciesUnited States, Canada
-
PfizerRecruitingMultiple Myeloma | Non-Hodgkin LymphomaChina